Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

TIC10 upregulates TRAIL expression in cancer cells, addressing delivery and stability issues of recombinant TRAIL, enhancing apoptosis and providing a broad-spectrum cancer treatment with improved efficacy.

JP2025159099APending Publication Date: 2025-10-17THE PENN STATE RES FOUND INC
6 Cites 0 Cited by

Patent Information

Application Number
JP2025133453
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2011-04-29
Filing Date
2025-08-08
Publication Date
2025-10-17

AI Technical Summary

Technical Problem

Existing treatments using recombinant TRAIL and TRAIL agonist antibodies face limitations such as short serum half-life, stability issues, high cost, and difficulty in delivering these agents across the blood-brain barrier, hindering their effectiveness in cancer therapy.

Method used

The use of TIC10, a small molecule TRAIL gene inducer, which upregulates TRAIL expression in both normal and cancer cells through a p53-independent mechanism, enhancing TRAIL-mediated apoptosis by inducing TRAIL expression and sensitizing tumor cells to apoptosis.

Benefits of technology

TIC10 effectively induces TRAIL expression, leading to sustained apoptosis in cancer cells and a bystander effect against tumors, demonstrating potential as a first-line treatment for various cancer types, including brain tumors, with improved efficacy and broader applicability compared to traditional TRAIL therapies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide small molecule TRAIL gene induction by normal cells and tumor cells as an anticancer therapy.SOLUTION: Methods and compositions related to TIC10 are described according to the aspects of the invention. The compositions and methods have utility in treating a disease, particularly cancer, in a subject (including human and other species) in need thereof. The compositions have utility in treating brain tumor in a subject in need thereof. According to one aspect of the invention, a method for treating a subject having or at risk of having cancer is provided, which method comprises a step of administering a pharmaceutically effective amount of TIC10 or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable carrier.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art